Risk assessment for cutaneous adverse drug reactions from antiretroviral agent

摘要

The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.

主权项

1. A method of assessing the risk of an HIV-infected patient for developing a cutaneous adverse reaction to nevirapine and treating the HIV-infected patient, comprising:
assessing the risk of the HIV-infected patient for developing a cutaneous adverse reaction to nevirapine by genotyping a sample obtained from the HIV-infected patient at the rs1576 single nucleotide polymorphism (SNP) locus in the CCHCR1 gene, wherein the presence of a homozygous C/C allele at the rs1576 SNP locus is indicative of no risk allele for the cutaneous adverse drug reaction to nevirapine, and administering nevirapine to the HIV-infected patient if the genotyped rs1576 SNP indicates the presence of a homozygous C/C allele at the rs1576 SNP locus, administering an antiretroviral drug therapy not including nevirapine to the HIV-infected patient if the genotyped rs1576 SNP indicates the presence of a C/G or G/G allele at the rs1576 SNP locus.